The future of antiretroviral therapy: challenges and needs

Moreno, Santiago; López Aldeguer, Jose; Arribas, José Ramón; Domingo, Pere; Iribarren, Jose Antonio; Ribera, Esteban; Rivero, Antonio; Pulido, Federico
May 2010
Journal of Antimicrobial Chemotherapy (JAC);May2010, Vol. 65 Issue 5, p827
Academic Journal
The introduction of combination antiretroviral therapy (cART) has substantially modified the natural history of HIV infection. At the beginning of the cART era the objective was focused on HIV-1-associated mortality and morbidity, but as this objective was accomplished other issues emerged, including toxicity, resistance and compliance with treatment. Moreover, the participation of other disease mechanisms, such as proinflammatory activity, in the so-called non-AIDS events is becoming increasingly important. To overcome these issues, therapeutic options have dramatically expanded, which has made the management of HIV-1-infected patients increasingly complex. The intense changes seen raise the question of what will be the future of HIV infection and its treatment. A projection into the future may help to reflect on current limitations, needs and research priorities, to optimize patient care. To debate on this topic a group of 38 experts has initiated The HIV 2020 Project, with the aim of reflecting on the future of HIV infection and identifying the needs that should be the attention of research in different areas. This document summarizes the group's conclusions on the future of antiretroviral treatment, presented as 20 relevant questions. Each question includes the current status of the topic and our vision for the future.


Related Articles

  • Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C. Hézode, Christophe; Fourati, Slim; Chevaliez, Stéphane; Scoazec, Giovanna; Soulier, Alexandre; Varaut, Anne; François, Murielle; Ruiz, Isaac; Roudot-Thoraval, Françoise; Mallat, Ariane; Pawlotsky, Jean-Michel // Clinical Infectious Diseases;6/1/2017, Vol. 64 Issue 11, p1615 

    We assessed the broadly used, off-label combination of sofosbuvir, daclatasvir, simeprevir, and ribavirin in direct-acting antiviral-experienced patients, as recommended in current guidelines despite scarce data. After 24 weeks' treatment, sustained virological response 12 weeks after the end of...

  • Meta-Analysis: Increased Mortality Associated with Hepatitis C in HIV-Infected Persons Is Unrelated to HIV Disease Progression. Ting-Yi Chen; Ding, Eric L.; Seage III, George R.; Kim, Arthur Y. // Clinical Infectious Diseases;11/15/2009, Vol. 49 Issue 10, p1605 

    Background. It is unclear whether coinfection with hepatitis C virus (HCV) increases mortality in patients with human immunodeficiency virus (HIV) infection during the era of highly active antiretroviral therapy (HAART). With use of a meta-analysis, we estimated the effect of HCV infection on...

  • Cellular Levels of HIV Unspliced RNA from Patients on Combination Antiretroviral Therapy with Undetectable Plasma Viremia Predict the Therapy Outcome. Pasternak, Alexander O.; Jurriaans, Suzanne; Bakker, Margreet; Prins, Jan M.; Berkhout, Ben; Lukashov, Vladimir V. // PLoS ONE;2009, Vol. 4 Issue 12, p1 

    Background: Combination antiretroviral therapy (cART), the standard of care for HIV-1 infection, is considered to be successful when plasma viremia remains below the detection limit of commercial assays. Yet, cART fails in a substantial proportion of patients after the apparent success. No...

  • The Evolution of Coreceptor Tropism in HIV-infected Patients Interrupting Suppressive Antiretroviral Therapy. Waters, Laura J.; Scourfield, Andrew T.; Marcano, Marie; Gazzard, Brian G.; Bower, Mark; Nelson, Mark; Stebbing, Justin // Clinical Infectious Diseases;3/1/2011, Vol. 52 Issue 5, p671 

    CCR5 antagonists may provide a well-tolerated switch option for patients experiencing tolerability or toxicity of their antiretroviral regimen. We analyzed stored samples from patients undergoing planned treatment interruptions for reasons other than virological failure, in order to analyze...

  • NIGELLA SATIVA CONCOCTION INDUCED SUSTAINED SEROREVERSION IN HIV PATIENT. Adekunle Onifade, Abdulfatah; Jewell, Andrew Paul; Adeola Adedeji, Waheed // African Journal of Traditional, Complementary & Alternative Medi;2013, Vol. 10 Issue 5, p332 

    Nigella sativa had been documented to possess many therapeutic functions in medicine but the least expected is sero-reversion in HIV infection which is very rare despite extensive therapy with highly active anti-retroviral therapy (HAART). This case presentation is to highlight the complete...

  • Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception. Machado, E. S.; Hofer, C. B.; Costa, T. T.; Nogueira, S. A.; Oliveira, R. H.; Abreu, T. F.; Evangelista, L. A.; Farias, I. F. A.; Mercadante, R. T. C.; Garcia, M. F. L.; Neves, R. C.; Costa, V. M.; Lambert, J. S. // Sexually Transmitted Infections;Apr2009, Vol. 85 Issue 2, p82 

    Objective: The potential adverse effects of antiretroviral drugs during pregnancy are discrepant and few studies, mostly from Europe, have provided information about pregnancy outcomes of those already on treatment at conception. The aim of this study was to investigate the impact...

  • The Art of Managing Human Immunodeficiency Virus Infection: A Balancing Act. Reiss, Peter // Clinical Infectious Diseases;11/15/2009, Vol. 49 Issue 10, p1602 

    In this article the author discusses the management of HIV infection. He examines the use of combination antiretroviral therapy for treatment and prevention of HIV infection. He looks into the findings of the Tenofovir-Emtricitabine or Abacavir-Lamivudine (STEAL) trial which examines the...

  • Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Nahid, Payam; Dorman, Susan E.; Alipanah, Narges; Barry, Pennan M.; Brozek, Jan L.; Cattamanchi, Adithya; Chaisson, Lelia H.; Chaisson, Richard E.; Daley, Charles L.; Grzemska, Malgosia; Higashi, Julie M.; Ho, Christine S.; Hopewell, Philip C.; Keshavjee, Salmaan A.; Lienhardt, Christian; Menzies, Richard; Merrifield, Cynthia; Narita, Masahiro; O'Brien, Rick; Peloquin, Charles A. // Clinical Infectious Diseases;10/1/2016, Vol. 63 Issue 7, p853 

    The American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America jointly sponsored the development of this guideline for the treatment of drug-susceptible tuberculosis, which is also endorsed by the European Respiratory Society and the US...

  • Reduction of Maternal Mortality with Highly Active Antiretroviral Therapy in a Large Cohort of HIV-Infected Pregnant Women in Malawi and Mozambique. Liotta, Giuseppe; Mancinelli, Sandro; Nielsen-Saines, Karin; Gennaro, E.; Scarcella, Paola; Magid, Nurja Abdul; Germano, Paola; Jere, Haswell; Guidotti, Gianni; Buonomo, Ersilia; Ciccacci, Fausto; Palombi, Leonardo; Marazzi, Maria Cristina // PLoS ONE;Aug2013, Vol. 8 Issue 8, p1 

    Background: HIV infection is a major contributor to maternal mortality in resource-limited settings. The Drug Resource Enhancement Against AIDS and Malnutrition Programme has been promoting HAART use during pregnancy and postpartum for Prevention-of-mother-to-child-HIV transmission (PMTCT)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics